Johnson & Johnson Analyst Price Targets - Benzinga

Johnson & Johnson

JNJNYSE

Trade with Public

Trade with Public

$254.78

1.850.73%

마지막 업데이트: Oct 6, 4:00 PM

$254.78

1.850.73%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 배당금 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

Johnson & Johnson Analyst Price Targets - Benzinga

Johnson & Johnson Analyst Price Targets

Wall Street analyst price targets and consensus rating for Johnson & Johnson (JNJ).

Price Target Range — 8 Quarters

Analyst Consensus — 17 Analysts

11Buy

6Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$265Upside to Avg. PT+4.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	RBC Capital	Trung Huynh	PT Raise	Outperform	$287→$290
Oct 5, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$298→$303
Sep 29, 2026	JP Morgan	Chris Schott	PT Raise	Neutral	$270→$285
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$290→$320
Sep 2, 2026	UBS	Michael Yee	PT Raise	Buy	$280→$320
Aug 6, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$270→$287
Aug 3, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$272→$282
Jul 17, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$270
Jul 16, 2026	Raymond James	Jayson Bedford	PT Raise	Outperform	$258→$265
Jul 16, 2026	RBC Capital	Shagun Singh	Maintained	Outperform	$287
Jul 16, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$263→$272
Jul 16, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$284→$294
Jul 13, 2026	TD Cowen	Michael Nedelcovych	PT Raise	Buy	$250→$300
Jul 13, 2026	RBC Capital	Shagun Singh	PT Raise	Outperform	$265→$287
Jul 10, 2026	B of A Securities	Tim Anderson	PT Raise	Neutral	$254→$263
Jul 8, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$283→$284
Jul 8, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$285→$298
Jun 26, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$266→$270
May 13, 2026	Leerink Partners	David Risinger	Upgrade	Market Perform→Outperform	$265
Apr 15, 2026	Barclays	Matt Miksic	PT Raise	Equal-Weight	$234→$255

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $290

RBC Capital analyst Trung Huynh maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and raises the price target from $287 to $290.

Benzinga Newsdesk

Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss

Analysts expect Johnson & Johnson's Q3 FY2027 sales to be in line, but EPS to be below consensus due to IPR&D dilution.

Priya Nigam

PRO
JP Morgan Maintains Neutral on Johnson & Johnson, Raises Price Target to $285

JP Morgan analyst Chris Schott maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $270 to $285.

Benzinga Newsdesk

PRO
HSBC Maintains Buy on Johnson & Johnson, Raises Price Target to $320

HSBC analyst Rajesh Kumar maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $290 to $320.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Johnson & Johnson, Raises Price Target to $320

UBS analyst Michael Yee maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $280 to $320.

Benzinga Newsdesk

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.

Vandana Singh